|
|
|
| Serum HDAC2 and IL-17A Levels in Patients with Chronic Obstructive Pulmonary Disease and Their Clinical Significance |
| LI Rui-min, DING Yan-yan, ZHANG Yong-xiang |
| Department of Respiratory Medicine, Daxing District People's Hospital, Beijing, 102600 |
|
|
|
|
Abstract 【Objective】 To investigate the levels of histone deacetylase (HDAC2) and interleukin-17A (IL-17A) in patients with chronic obstructive pulmonary disease (COPD) and to analyze the clinical significance. 【Methods】 Patients with COPD who were treated in our hospital from August 2017 to May 2018 were selected as the study subjects (COPD group,n=40), and healthy adults who received physical examination in the same period were selected as the control group (n=40). The levels of HDAC2, IL-17A, pulmonary function and blood gas were compared between the two groups, and the correlation of the levels of HDAC2 and IL-17A with pulmonary function and blood gas was analyzed. 【Results】 The levels of HDAC 2,pH and arterial partial pressure of oxygen (PaO2) in the COPD group were lower than those in the control group (P<0.05), and the levels of IL-17A and arterial partial pressure of carbon dioxide (PaCO2) were higher than those in the control group (P<0.05). The forced vital capacity (FVC), FEV1/FVC, maximum expiratory mid-flow (MMEF) and maximum expiratory flow (PEF) were significantly lower in the COPD group than in the control group (P<0.05). The level of HDAC2 in COPD patients was negatively correlated with PaCO2, and positively correlated with FEV1/FVC, FVC, MMEF, PEF, PH and PaO2 levels. The level of IL-17A was positively correlated with PaCO2 level, and negatively correlated with FEV1/FVC, FVC, MMEF, PEF, PH and PaO2 levels. 【Conclusion】 The level of HDAC2 is lower and level of IL-17A is higher in COPD patients. They are closely related to lung function and blood gas index.
|
|
Received: 14 November 2018
|
|
|
|
|
|
[1] Shah NM, Murphy PB. Chronic obstructive pulmonary disease and sleep[J].Curr Opin Pulm Med,2018,24(6):561-568.
[2] 王卫彪. 组蛋白去乙酰化酶2在慢性阻塞性肺疾病急性加重期诊疗中的意义[J].浙江预防医学,2016,28(6):553-556.
[3] 张之海. IL-17、TLR4、P2X7基因多态与慢性阻塞性肺疾病的关联研究[J].中华疾病控制杂志,2018,22(2):142-146.
[4] 张文娟,路东明,宗晓福,等. 血清脂联素、IL-8及IL-17在COPD急性加重期诊断中的临床价值研究[J].湖南师范大学学报(医学版),2016,13(6):76-78.
[5] 郝艳芳, 孙文英, 赵永芳,等. Nogo-B对慢性阻塞性肺病继发肺心病预测价值[J].现代仪器与医疗, 2017, 23(1):95-97.
[6] 蔡杰. COPD患者血清IL-17A和CXCL12浓度与病情及淋巴滤泡生成的关系[J].重庆医学,2016,45(30):4255-4258.
[7] 黄超.COPD患者血清IL-17与8-iso-PGF(2α)水平变化及临床意义[J].华北理工大学学报(医学版),2017,19(5):352-355.
[8] 晏斌林,顾为丽,杜娟,等. 慢性阻塞性肺疾病患者呼出气冷凝液IL-17、IL-10、8-iso-PG的测定及临床意义[J].中国呼吸与危重监护杂志,2017,16(2):142-146.
[9] 杜海莲.慢性阻塞性肺疾病患者血清IL-17、IL-6、IL-8、CRP、TNF-α的变化及其相关性[J].昆明医科大学学报,2015,36(9):95-97.
[10] 何小双.慢性阻塞性肺疾病患者呼出气冷凝液中白介素8、白介素17水平及其与第1秒用力呼气末容积占预计值百分比的关系研究[J].中国全科医学,2016,19(1):63-67. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(3): 611-612. |
|
|
|
|
2019, Vol. 36 
